bpc 157 drug Sequential biopharmaceutical and regulatory barriers limiting BPC-157 Did the FDA Just Approve

Although 5-Amino-1MQ is still considered an emerging longevity compound, its ability to inhibit NNMT positions it as one of the most promising tools for preserving NAD+ and supporting mitochondrial health, especially when combined with NAD+ therapy

The full 12-week schedule requires 5660 injections, depending on whether the maintenance phase is dosed 2-3x per week

Patients must demonstrate competence before being approved for independent home administration

Iron deficiency affects approximately 72% of women experiencing hair loss, making it one of the most common underlying causes [3]

The additional daily injections, timing requirements (fasted administration for AOD 9604), and cost may not justify whatever incremental benefit exists